FDA recall, , Moderate risk
Vitalant Apheresis Platelets, Leukocytes Reduced, Pathogen Reduced
Apheresis Platelets, Leukocytes Reduced, Pathogen Reduced may have been exposed to unacceptable temperatures during an extended transit time.
Vitalant began this recall on Oct 2, 2025. FDA posted it on Nov 16, 2026, the day the recall ended.
What happened
Vitalant, a company based in Bismarck, North Dakota, is recalling Vitalant Apheresis Platelets, Leukocytes Reduced, Pathogen Reduced. The company started the recall on its own on October 2, 2025. The product was distributed in North Dakota. The FDA added the recall to its Enforcement Report and classified it on November 16, 2026.
What to do
Biologics such as blood, tissue and vaccines are usually given by hospitals and clinics. If you had a transfusion, transplant, infusion or vaccine, ask the place that treated you whether this product was used. If they contact you, follow their advice.
What was recalled
Hospitals, clinics and blood banks match these details against their records.
Apheresis Platelets, Leukocytes Reduced, Pathogen Reduced
- Unit number
- W03622515434600Z
- W03622516525900M
- W03622516525600S
Recall details
- Posted by FDA
- Recall began
- Status
- Ended Nov 16, 2026
- Weekly archive
- Listed the week of Nov 16, 2026
- Distributed to
- Recalled by
- VitalantBismarck, North Dakota
- Hazard
- Processing problem
- Risk
Moderate risk
Its use may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- FDA event number
- 100030
- Recall number
- B-0007-2027
- Recall type
- Started by the company
Timeline
FDA's Enforcement Report is its public list of recalls; FDA posts a recall by adding it there.
Vitalant began the recall
FDA posted the recall to its Enforcement Report, rated it Class II (moderate risk) and closed it
Added to Recall Canary
